Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant…
Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the…
Read More...
Read More...